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Abstract 1 
 2 
Background: The Dietary Approaches to Stop Hypertension (DASH) has been shown to lower blood 3 
pressure in the West. However, the real-life impact of DASH on reducing cardiovascular (CV) risk in 4 
routine clinical setting has not been studied. 5 
 6 
Methods: A parallel-group, open-labelled, physician-blinded, randomised controlled trial was 7 
conducted in January-June 2013 and followed up for 6- and 12-months in primary care settings in 8 
Hong Kong. Patients newly diagnosed with grade 1 hypertension (aged 40-70 years) who had no 9 
concomitant medical conditions requiring dietary modifications were consecutively recruited. 10 
Subjects were randomised to standard education (usual care) (n=275), or usual care plus dietitian-11 
delivered DASH-based dietary counselling in a single one-to-one session (intervention) (n=281). 12 
Primary outcomes were the changes in estimated 10-year CV risk. 13 
 14 
Results: Outcome data were available for 504 (90.6%) and 485 (87.2%) patients at 6 and 12 months, 15 
respectively. There was no difference in the reduction of 10-year CV risk between the two groups at 6 16 
months (-0.13%, 95% confidence interval [95%CI] -0.50% to 0.23%, p=0.477) and 12 months (-17 
0.08%, 95%CI -0.33% to 0.18%, p=0.568). Multivariate regression analyses showed that male 18 
subjects, younger patients, current smokers, subjects with lower educational level, and those who 19 
dined out for main meals for ≥4 times in a typical week were significantly associated with no 20 
improvements in CV risk. 21 
 22 
Conclusions: The findings may not support automatic referral of newly diagnosed grade 1 23 
hypertensive patients for further one-to-one dietitian counselling. Patients with those risk factors 24 
identified should receive more clinical attention to reduce their CV risk.  (250 words) 25 
 26 
Clinical Trial Registration: ChiCTR-TRC-13003014 (http://www.chictr.org.cn/enindex.aspx) 27 
Abbreviations: DASH, Dietary Approaches to Stop Hypertension; CV, cardiovascular; CI, 28 
confidence interval 29 
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Introduction 30 
Uncontrolled high blood pressure (BP) remains a leading cause of cardiovascular disease (CVD), 31 
which plays a role in more than 31% of all global deaths [1]. The Dietary Approaches to Stop 32 
Hypertension (DASH) diet has been recommended in international guidelines for hypertension 33 
management [2-5]. Evidence mostly come from the original landmark trial [6] and subsequent feeding 34 
studies which demonstrated that short-term BP changes could lead to substantial reductions in BP [7-35 
9]. Multi-factorial lifestyle components with multiple intervention sessions and frequent reminders 36 
were also adopted in DASH-series trials [10, 11], yet the long-term effectiveness of the DASH diet 37 
per se, if introduced into routine practice, is unclear. 38 
 39 
Existing guidelines including the Seventh Report of the Joint National Committee, however, do not 40 
explicitly recommend how DASH should be delivered [2]. Trials that were designed to provide food 41 
to patients from research kitchens were relatively less applicable and feasible to clinical practice, 42 
wherein the one-off dietary counselling is most common in routine patient care. A previously 43 
described randomised controlled trial among grade 1 hypertensive patients in Hong Kong showed that 44 
one-off dietary counselling did not confer additional benefits on BP, body mass index, and lipid 45 
profiles [12]. Nevertheless, in light of the increasing atherosclerotic burden [13], it is uncertain 46 
whether DASH diet counselling could benefit patients in terms of reducing long-term cardio-vascular 47 
(CV) risks [14, 15]. To the best of our knowledge, no evidence exists as to whether patients newly 48 
diagnosed as having grade 1 hypertension should be referred to dietitian care for early DASH 49 
counselling, or just be offered brief advice on fundamental dietary principles from primary care 50 
physicians. A trial with CV risk as an outcome is important as it is widely recognised that patients 51 
with an estimated 10-year CV risk greater than 20% should be prescribed lipid-lowering agents, 52 
amongst other more intensive interventions. 53 
 54 
This study tested the a priori hypothesis that one-off dietary counselling by dietitian based on the 55 
DASH recipe could reduce the estimated 10-year cardiovascular risk among hypertensive patients in 56 
real clinical setting. We also studied the factors independently associated with no improvements in 57 
cardiovascular risk among the same cohort of hypertensive patients recruited in primary care clinics. 58 
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Methods 59 
Study design 60 
A detailed description of the trial design has been reported [12]. This was a parallel-group, open-61 
labelled, physician-blinded, randomised clinical trial with enrolment (January-March 2013) at two 62 
General Outpatient Clinics or at community health seminars through a primary care network in the 63 
New Territories East Cluster, Hong Kong. The study was approved by the Joint Chinese University of 64 
Hong Kong-New Territories East Cluster Clinical Research Ethics Committee, Hong Kong. The study 65 
protocol complied with the Declaration of Helsinki. The trial was prospectively registered (ChiCTR-66 
TRC-13003014). Each trial participant provided written informed consent. 67 
 68 
Patients 69 
To be eligible, subjects had to be (1) Chinese patients aged 40-70 years; (2) newly diagnosed with 70 
grade 1 hypertension by trained clinical staffs according to a standard protocol [4]; and (3) currently 71 
receiving no antihypertensive drug therapies. The exclusion criteria were the presence of (1) medical 72 
conditions which required dietary control (e.g. diabetes and gout); (2) diseases with drug treatments 73 
that potentially interfered with the effectiveness of diet on the changes of blood lipid levels (e.g., 74 
obstructive sleep apnoea syndromes or dyslipidemia); (3) previous cardiovascular event. All 75 
participants verbally agreed to attend follow-up appointments at 6 and 12 months. 76 
 77 
Randomisation and masking 78 
Computer-generated numbers with a block size of 6 and an allocation ratio of 1:1 were used for group 79 
allocation. The research nurse opened the opaque envelope in which the randomised sequence was 80 
sealed, and then notified patients into either intervention or control group. The dietitian and study 81 
subjects were not masked to group allocation, but the attending physicians, research assistants, and 82 
clinical staff involved in the outcome data collection were blinded. 83 
 84 
Procedures and risk factor measurement 85 
Patient screening was performed to ascertain the subject eligibility. BP was determined by an 86 
automated sphygmomanometer device (ALPK2 DS-182) which was validated regularly. The BP was 87 
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measured in the right arm with the use of an appropriately sized cuff according to standardised 88 
protocol that was used in prior studies [16, 17]. BP measurements were obtained after the participants 89 
sat quietly for 5 minutes, at least one hour after the subject’s last meal intake, and at least 30 minutes 90 
after cigarette smoking or consuming caffeinated beverages. The average of three BP measurements 91 
separated by at least 30 seconds were taken. Those with SBP of 140-159 mmHg and/or DBP of 90-99 92 
mmHg were diagnosed as having grade 1 hypertension [4, 5]. A weight scale under periodic 93 
calibration was used to measure body weight in light clothing, and a wall-mounted stadiometer was 94 
used to measure body height without shoes. Usual care was provided to all participants (both groups). 95 
A DASH dietary counselling appointment was arranged immediately after usual care in the 96 
intervention arm only. Blood samples after an 8-hour fast were taken from all participants for 97 
measuring lipid profiles. The laboratory analysis was centrally undertaken at the Lek Yuen Health 98 
Centre, Hospital Authority, Hong Kong. 99 
 100 
Usual care advice 101 
Usual care was offered by the attending physician, following a standard educational pamphlet in 102 
which contents were tailored for hypertensive patients in all public primary care clinics in Hong 103 
Kong. The core components consisted of (1) the definition and aetiology of hypertension; (2) the 104 
diagnosis and possible complications of grade 1 hypertension; (3) annual assessment to ensure 105 
satisfactory BP control; and (4) general recommendations including smoking cessation, moderation of 106 
alcoholic consumption, weight reduction as appropriate, regular aerobic exercise, balanced diet with 107 
sodium reduction and reduced fat, as well as adequate sleep and rest. The format was standardised in a 108 
training workshop by the principal investigator (MCSW). The usual care lasted for 3-5 minutes, 109 
resembling the routine clinic practice. 110 
 111 
DASH dietary counselling 112 
Only subjects in the intervention arm received a further 25-minute one-off dietary counselling, offered 113 
by an experienced, registered dietitian (MKWM). The counselling was based on the DASH 114 
recipe [18] and were standardised in a pilot study to ensure that the counselling was feasible and 115 
intelligible to all participants. The contents included: (1) the nature and major components of the 116 
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DASH diet, (2) benefits of the diet, and (3) individualised meal plans that were tailored in Asia [19]. 117 
The individualised DASH diet goals were recommended with respect to high consumption of fruits 118 
(4-5 serves/day) and vegetables (4-5 serves/day), low-fat dairy products (2-3 serves/day), lean meats, 119 
poultry, and fish (<6 serves/day), and nuts, seeds, and legumes (4-5 serves/week). The goals also 120 
included the achievement of limited intake of sweets, added sugars (<5 serves/week), and fats and oils 121 
(2-3 serves/day) [18]. Reducing salt intake to less than 5 grams per day with no added salt use was 122 
also encouraged [19]. Participants were examined regarding their experiences with the counselling 123 
and the extent of understanding the DASH principles. The counselling process was documented for 124 
quality assurance. 125 
 126 
Follow–up assessment 127 
All participants attended follow-up clinic visits at 6 and 12 months with BP measurements and fasting 128 
blood samples taken. Subjects with abnormal BP or lipid levels (judged by the physicians) were 129 
referred to specialists. The dietary component intakes of the eight food groups (grains; vegetables; 130 
fruits; dairy; meat, poultry, fish, and eggs; nuts, seeds, and legumes; fats and oils; sweets) were 131 
assessed by a locally validated food frequency questionnaire [20, 21]. No significant between-arm 132 
differences were found, except that the intervention group reported marginally higher consumption of 133 
vegetables and diary at 12 months [12]. 134 
 135 
Outcomes 136 
Primary outcomes were the changes in estimated 10-year risk of "hard" CV events comprising acute 137 
myocardial infarction, sudden death, and other coronary deaths [22]. A recalibrated and validated 138 
Chinese version of the Framingham equation derived from the Chinese Multi-provincial Cohort Study 139 
was used [22]. The estimated 10-year CV risk (P) is: P=1−S(t)exp(f[x,M]) f(x,M)=Beta1(x1−M1) + . . . + 140 
Betap(xp−Mp) where S(t) is the 10-year survival rate at the mean values of the risk factors; Beta1 . . . 141 
Betap are the coefficients in the regression model; x1 . . . xp represent individual-level risk factors; and 142 
M1 . . . Mp are the mean values of the risk factors in the cohort. Covariates included age, gender, and a 143 
series of modifiable CV risk factors including smoking status, BP, total cholesterol (TC), and high-144 
density lipoprotein cholesterol (HDL-C). The algorithm followed the methods used in the Chinese 145 
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recalibration of the Framingham equation [22]. The effects of risk factors at differing ages and levels 146 
of the other risk factors are assumed constant [23]. The BP was categorised as optimal BP (having 147 
SBP <120 mmHg and DBP <80 mmHg with no antihypertensive medication taking), pre-hypertension 148 
(having SBP of 120-139 mmHg and/or DBP of 80-89 mmHg,), grade 1 hypertension, and grade 2-4 149 
hypertension (having SBP ≥160 mmHg and/or DBP ≥100 mmHg). Cut-off points of 200 mg/dL (5.18 150 
mmol/L) and 240 mg/dL (6.22 mmol/L) were applied to categorise the TC level into <160, 160-199, 151 
200-239, 240-179, and ≥280 mg/dL. The HDL-C level was classified as <35 mg/dL (0.91 mmol/L), 152 
35-44, 45-49, 50-59, and ≥60 mg/dL. 153 
 154 
Statistical analysis 155 
The primary outcomes were changes in the 10-year CV risk estimated on the basis of BP, TC, and 156 
HDL-C at 6 and 12 months, respectively. Secondary outcomes consisted of gender-stratified changes 157 
in CV risk factors between baseline and follow-ups. We aimed to detect an expected difference in 158 
DBP change of 2.0 mmHg at repeated follow-ups, which was considered clinically significant 159 
between the intervention and control arms. Previous literature reported a standard deviation of the 160 
DBP change of approximately 5.3 mmHg [6], and therefore we assumed a more conservative value of 161 
7.0 mmHg in this study. The G*Power 3.1.0 gave a sample size of 252 per group that provided at least 162 
85% power at the two-sided 5% significance level. A cumulative frequency analysis was conducted to 163 
illustrate the gender-stratified changes in BP at 12 months by groups. We fitted a linear-regression 164 
model in which analysis of covariance was performed to compare between-group differences 165 
(intervention minus usual care) in the changes of 10-year CV risk, with adjustment for the effects of 166 
other factors and baseline outcome measures. The last observation carried forward (LOCF) imputation 167 
method was used for managing missing data in sensitivity analysis. Factors associated with no 168 
improvements in the 10-year CV risks were initially evaluated by chi-square tests in univariate 169 
analysis, followed by a binary logistic regression analysis to test the association between all 170 
potentially independent variables and the outcome variable. A final regression model was then 171 
constructed using a backward stepwise algorithm that allowed for covariate re-entry with all 172 
covariates having p values of ≤0.10 retained in the model. Data analyses were performed in 173 
accordance with the CONSORT statement [24], using IBM SPSS Statistics 20.0 (Chicago, IL, USA). 174 
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Results 175 
Participant characteristics 176 
A total of 556 patients met the inclusion criteria and were randomised into either usual care (n=275, 177 
49.5%) or DASH dietary counselling (n=281, 50.5%), respectively. At 6 and 12 months, 504 and 485 178 
patients were available for analysis of the primary end-points (CONSORT Figure 1). The first 179 
subject enrolled in January 2013, and the last subject completed the 12-month assessment in June 180 
2014. The average age was 55.2 years and 49.1% were male. Baseline characteristics of the two 181 
groups were comparable across the background variables (Table 1). 182 
 183 
Changes in risk factors and estimated 10-year cardiovascular risk 184 
None of the individual CV risk factors was significantly different between the two groups at baseline 185 
and 12 months (Table 2). The reductions in BMI were observed in both groups with no significant 186 
between-group differences (-0.05, 95%CI -0.20 to 0.10, p=0.490). The crude cumulative percentage 187 
of subjects in the intervention group who experienced ≥2mmHg reduction in DBP or ≥3mmHg 188 
reduction in SBP were similar when compared to that in the control group. No significant between-189 
group differences were detected for the magnitude of BP reductions (Figure 2). Patients in both 190 
groups exhibited significant improvements in their 10-year CV risk over time simultaneously. The two 191 
groups, however, did not report any significant between-group difference in the changes of 192 
cardiovascular risk at 6 months (-0.13%, 95%CI -0.50% to 0.25%, p=0.477) and 12 months (-0.08%, 193 
95% CI -0.33% to 0.18%, p=0.568) (Table 3). 194 
 195 
Factors associated with no improvements in 10-year cardiovascular risk 196 
From binary logistic regression analysis with non-optimisation of cardiovascular risk as an outcome, 197 
it was found that male patients (adjusted odds ratio [aOR]=1.68, 95%CI 1.12 to 2.52, p=0.012), 198 
younger subjects (<55 years, aOR=1.49, 95%CI 1.00 to 2.23, p=0.049), current smokers (aOR=2.93, 199 
95%CI 1.35 to 6.36, p=0.007), those with lower educational level (junior secondary or below, 200 
aOR=1.75, 95%CI 1.15 to 2.66, p=0.009) and subjects who dined out frequently for the main meal 201 
(aOR=1.85, 95%CI 1.03 to 3.32, p=0.038) were least likely to have their cardiovascular risk 202 
optimised (Table 4). 203 
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Discussion 204 
Statement of principle findings 205 
This randomised clinical trial evaluated the effectiveness of dietitian counselling based on the DASH 206 
recipe among newly diagnosed grade 1 hypertensive patients in the real primary care setting. The 207 
estimated 10-year CV risk decreased significantly in both groups from baseline to 12 months, yet the 208 
DASH counselling produced no additional benefits. Male subjects, younger patients, current smokers, 209 
subjects with lower educational level, and those who dined out frequently were less likely to be 210 
benefited from the dietary counselling to the optimisation of CV risk. These findings may not support 211 
the value of automatic referral of grade 1 hypertensive patients to one-off dietitian care when newly 212 
diagnosed. Patients with risk factors identified in this study warrant more clinical attention as they 213 
might be more resistant to CV risk improvement over time. 214 
 215 
Relationship with other studies 216 
The effectiveness of the DASH diet was largely established on the basis of previous controlled 217 
feeding trials, which indicated that individuals given prepared or prescribed DASH diet had lower BP, 218 
compared with controls [6-9, 15]. The DASH diet, as a result of these trials conducted in the research 219 
kitchen context, was recommended in most hypertension guidelines [2-5, 25] - and also an example of 220 
healthful eating pattern [26]. The US Nurses Health longitudinal study showed that the long-term 221 
adherence to DASH-style diet could benefit healthy female nurses with regard to reduced CV 222 
risk [27]. Nevertheless, both studies performed in research kitchen and among free-living health-223 
conscious adults carried the underlying nature of optimum adherence to the DASH diet. The 224 
compliance may also be substantially optimised by intensive reminders, weekly peer-group sessions, 225 
daily food consumption diaries [28], or multiple intervention sessions with calorie and nutrient intake 226 
monitoring [10, 11]. Our study, in contrast, was performed in the real clinical setting wherein the 227 
dietary counselling practices are often delivered to grade 1 hypertensive patients on a one-off basis 228 
without follow-up prompts [29-31]. 229 
 230 
Previous translational efforts have been made to estimate the overall effect of DASH diet on CV risk 231 
estimates on the basis of risk factors, given the cost and logistical consideration of long-term trial with 232 
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"hard" CV events as the actual clinical endpoint [32]. The Framingham-based risk equation [22, 33] 233 
was a widely-used risk prediction algorithm to estimate 10-year CV risk. An earlier meta-regression 234 
analysis of randomised trials showed that being overweight made the largest contribution to 235 
hypertension [34]. The short-term effect of consuming reduced fats and oils in the DASH diet on 236 
cholesterol could be therefore more apparent for overweight people who lose weight [35]. In our trial, 237 
the study participants in both groups demonstrated weight reductions with similar magnitude on 238 
follow-ups. We did not specifically collect information on the dietary intakes of fatty acid in the two 239 
groups, and therefore we could not rule out the possibility that subjects in the intervention group may 240 
also have reduced intake of unsaturated fat when limiting the overall consumption of dietary fats and 241 
oils simultaneously. Albeit the intake of unsaturated fat may affect HDL-C level (one of the 242 
components of the Framingham risk equation), it is not likely that the intake changes can explain the 243 
relative absence of intervention effects as no significant between-group differences in the changes of 244 
lipid levels were detected in the present study. The original DASH study had the potential to decrease 245 
estimated 10-year CV risk by 18% [36]. In the PREMIER study, subjects who received the DASH 246 
diet plus combined multi-component lifestyle behavioural modifications had similar decrease in 10-247 
year CV risk when compared to the advice-only control at 6 months, but reported significantly 248 
reduced risk by 12% at 18 months [10, 37]. Another US study has shown a decreased 10-year CV risk 249 
by 12.1% from an 8-week DASH diet feeding [38]. We used a Chinese version of the Framingham 250 
equation in which the relationship between changes in estimated 10-year CV risk with actual 251 
subsequent CV event was recalibrated and validated [22]. The reduction of predicted 10-year CV risk 252 
by 19.3% (dropped from 3.37% to 2.72% at 12 months) observed in the intervention group was 253 
comparable to that in previous studies, implying the validity of the trial fidelity. Moreover, a CV risk 254 
reduction by 17.1% (dropped from 2.98% to 2.47% at 12 months) in the control arm with no between-255 
group differences therefore suggesting favourable effects in both groups. 256 
 257 
Meaning of the study 258 
Given that the DASH diet has been adopted in hypertension guidelines and reference frameworks for 259 
hypertension care, we would not regard our work as a simple replication study of previous trials. By 260 
contrast, our trial provides data for the intervention as adapted for implementation in real-world 261 
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clinical setting wherein both the DASH diet and the dietitian-delivered counselling in a single one-to-262 
one session were tested as a combined intervention. We showed similarity in responses in the 263 
reduction of 10-year CV risk between intervention and control groups. One may criticise the 264 
inadequate "dose" of the DASH diet from a one-off counselling session; albeit it is relatively rare for 265 
real-world dietary counselling to be offered more frequently than once a year particularly among those 266 
with newly diagnosed mildly-elevated BP [29-31]. The real-life dietary adherence may also be 267 
influenced by contextual factors such as the costs of foods and the taste of low-fat foods, as evidence 268 
revealing that the concordance with the DASH diet tended to be lower in free-living population [39]. 269 
Moreover, both the UK and US studies have argued that greater accordance with the DASH food 270 
group targets could be associated with higher dietary costs indeed [40, 41]. This may suggest a 271 
reconsideration of the DASH diet given the cultural acceptability and structural barriers to modifying 272 
eating habits, despite that we were unable to account for the cost-effectiveness in the present trial. The 273 
US National Health and Nutrition Examination Survey (NHANES) data illustrated that only around 1 274 
in 5 individuals practically followed an eating plan modelled on the DASH diet in daily life [42]. It 275 
has been argued that the limited time spent on providing adequate instructions due to the 276 
reimbursement structure in the US healthcare context [42] may be at play. Our study has prolonged 277 
the dietitian-patient consultation time to almost 30 minutes with detailed educational materials, yet the 278 
similar magnitude in the CV risk reductions obtained in both groups implied that the prior assumption 279 
related to dietary counselling itself may be misstated. 280 
 281 
Our study showed that factors associated with lower odds of CV risk improvements included younger 282 
age and lower education level, which were echoed in a number of other studies that reported the 283 
decreased likelihood of changing dietary patterns among these subjects [42]. We reported differences 284 
in responses in the CV risk reductions between males and females. This was undertaken post hoc due 285 
to observed differences, and the exploratory results should be interpreted cautiously. The initial CV 286 
risk was relatively lower for males, which might reduce the chance of achieving significant changes 287 
following the intervention, albeit the baseline differences were controlled for in the analysis. Further 288 
study specifically designed to allow separate gender analyses may elucidate the gender-specific 289 
responses. The study recruitment was conducted in Hong Kong, where dinning out is an integral part 290 
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of its culture. Subjects who often go out for the main meal of the day were less likely to optimise 10-291 
year CV risk. This supports the criticism on the widespread dining-out trend with fast-food culture 292 
which appears to embrace rich calorie and poor nutrient [13, 42]. 293 
 294 
The study findings are the most directly applicable to routine practice in the Chinese population, with 295 
wider relevance to primary prevention in health-care system in other middle- and low- income 296 
countries. The standard education from physician’s usual care advice alone in this study has shown a 297 
persistent BP reduction by an amount similar to that achieved with additive DASH-based dietary 298 
counselling. This implied that usual physician care alone might be adequate to maintain a significant 299 
improvement in CV risk over time, and if translated into clinical practice, one could expect substantial 300 
cost-saving. The possibility of reducing or avoiding further dietitian referral could lead to substantial 301 
clinical benefits in terms of streamlined counselling process and public health impact with regard to 302 
cutting unnecessary cost to individuals and the healthcare system. 303 
 304 
Strengths and weaknesses of the study 305 
This randomised controlled trial was sufficiently powered and included subjects who were treatment-306 
naive to both antihypertensive medications and other community-based programs. All individuals 307 
were newly-diagnosed, and patients with other medical conditions requiring dietary modification were 308 
excluded to eliminate possible confounder effects. The similarity of baseline characteristics between 309 
the two groups and the strict adherence with study protocols further improved the internal validity and 310 
robustness of the findings. The vast majority of patients received no drug treatments during the entire 311 
study period. The proportions of individuals who developed comorbidities or received further drug 312 
treatments for safety reasons were relatively small, and were similar between the two arms. In the 313 
sensitivity analysis wherein the LOCF imputation methods were applied for missing data (less than 314 
10%) and patients with drug therapies were excluded, similar findings were yielded. Nevertheless, 315 
weakness of this study should receive attention. Firstly, we used 10-year CV risk estimates instead of 316 
actual CV events as the primary outcome. A universal critique might be the accuracy and validity with 317 
respect to how closely the predicted outcomes agree with the actual outcomes. However, the Chinese 318 
version of the risk equation has been validated in the ethnic Chinese who comprised the entire study 319 
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population in our trial. The use of risk estimation instead of the incidence of actual CV events after 10 320 
years allows greater feasibility of trial implementation with higher retention rate. Secondly, the 10-321 
year CV risk presented at baseline was relatively low due to the nature of mild hypertension, and the 322 
Hawthorne effect [43] in the clinic-based data collection may exist, which could be partially 323 
responsible for the lack of effect in the intervention group. Nevertheless, the study participants in the 324 
physician’s usual care group still reported a significant CV risk reduction similar to those in the 325 
intervention group. This could be broadly applied to the general population with wider relevance to 326 
primary prevention. 327 
 328 
Conclusions 329 
The automatic referral of newly diagnosed grade 1 hypertensive patients for further one-to-one 330 
dietitian counselling in a single session may not be supported on the basis of the trial evidence found 331 
for its effectiveness in the routine clinical setting. More clinical attention are required on male 332 
subjects, younger patients, current smokers, subjects with lower educational level, and those frequent 333 
dine-outers, as they were less likely to be responsive to long-term CV risk improvements. It is 334 
possible that adding more intensive or multiple intervention sessions might shift the evidentiary 335 
balance in favour of the intervention; however, usual physician care alone might be adequate to 336 
maintain a significant improvement in CV risk over time. One may therefore expect substantial cost-337 
saving in middle- and low-income countries wherein primary care physicians are being strengthened 338 
as the locus of responsibility for the long-term care. 339 
 340 
 341 
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Table 1: Background characteristics of the trial participants 
 
Characteristic Usual care group DASH counselling group P value All participants 
 (n=275) (n=281)  (N=556) 
Sex (M/F) 142/133 131/150 0.237* 273/ 283 
Males     
  Age, years 54.7 (5.0) 55.4 (5.0) 0.980 55.0 (5.0) 
  BMI, kg/m
2
 24.28 (2.85) 24.53 (2.58) 0.389 24.40 (2.72) 
  SBP, mmHg 143.7 (7.6) 144.3 (7.4) 0.503 144.0 (7.5) 
  DBP, mmHg 90.9 (5.6) 91.7 (5.5) 0.220 91.3 (5.6) 
  TC, mmol/L 5.39 (0.88) 5.45 (0.78) 0.556 5.41 (0.83) 
  HDL-C, mmol/L 1.43 (0.41) 1.41 (0.35) 0.619 1.42 (0.38) 
  LDL-C, mmol/L 3.27 (0.78) 3.41 (0.77) 0.157 3.33 (0.78) 
  TG, mmol/L 1.48 (0.78) 1.38 (0.81) 0.275 1.43 (0.80) 
  Senior education or above 101 (71.6) 90 (69.8) 0.737* 191 (70.7) 
  Family history of hypertension 97 (68.8) 84 (64.6) 0.466* 181 (66.8) 
  Current smokers 16 (11.3) 15 (11.6) 0.942* 31 (11.5) 
  Comorbidities 0.14 (0.42) 0.16 (0.40) 0.794 0.15 (0.41) 
Females     
  Age, years 55.2 (5.3) 55.3 (6.0) 0.222 55.3 (5.7) 
  BMI, kg/m
2
 24.15 (3.31) 23.82 (3.00) 0.438 23.98 (3.15) 
  SBP, mmHg 146.2 (6.9) 146.0 (8.1) 0.743 146.1 (7.5) 
  DBP, mmHg 89.0 (7.2) 89.4 (8.1) 0.667 89.2 (7.7) 
  TC, mmol/L 5.45 (0.76) 5.62 (0.83) 0.078 5.54 (0.80) 
  HDL-C, mmol/L 1.67 (0.42) 1.66 (0.45) 0.811 1.67 (0.44) 
  LDL-C, mmol/L 3.24 (0.74) 3.37 (0.84) 0.159 3.31 (0.79) 
  TG, mmol/L 1.18 (0.56) 1.30 (0.61) 0.096 1.25 (0.59) 
  Senior education or above 62 (47.0) 70 (47.6) 0.914* 132 (47.3) 
  Family history of hypertension 94 (71.2) 102 (69.4) 0.739* 196 (70.3) 
  Current smokers 2 (1.5) 1 (0.7) 0.500* 3 (1.1) 
  Comorbidities 0.28 (0.56) 0.22 (0.52) 0.404 0.25 (0.54) 
 
Values are presented as mean (SD) for continuous variables and number (%) for categorical variables. SD, 
standard deviation; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total 
cholesterol; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; TG, 
triglyceride. 
*
 
Use of chi-square tests
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Table 2: Change of CV risk factors in the Framingham equation in the usual care group and 
DASH counselling group from baseline to 12 months 
 
Risk Factors Baseline    12 months   
 Usual care Intervention P  Usual care Intervention P 
Males        
Blood Pressure   --    0.880 
  Optimal 0 (0.0) 0 (0.0)   7 (5.7) 9 (7.9)  
  Pre-hypertension 0 (0.0) 0 (0.0)   41 (33.6) 38 (33.3)  
Grade 1 hypertension 142 (100.0) 131 (100.0)   65 (53.3) 57 (50.0)  
Grade 2-4 hypertension 0 (0.0) 0 (0.0)   9 (7.4) 10 (8.8)  
TC, mg/dL 
  
0.858 
   
0.712 
<160 12 (9.0) 7 (5.9)   8 (6.6) 5 (4.5)  
160-199 43 (32.3) 39 (32.8)   50 (41.0) 49 (44.5)  
200-239 57 (42.9) 53 (44.5)   48 (39.3) 46 (41.8)  
240-279 20 (15.0) 18 (15.1)   15 (12.3) 10 (9.1)  
≥280 1 (0.8) 2 (1.7)   1 (0.8) 0 (0.0)  
HDL-C, mg/dL 
  
0.745    0.503 
<35 9 (6.8) 8 (6.7)   8 (6.6) 5 (4.5)  
35-44 27 (20.3) 20 (16.8)   29 (23.8) 17 (15.5)  
45-49 14 (10.5) 13 (10.9)   12 (9.8) 12 (10.9)  
50-59 39 (29.3) 44 (37.0)   34 (27.9) 37 (33.6)  
≥60 44 (33.1) 34 (28.6)   39 (32.0) 39 (35.5)  
Females 
  
     
Blood Pressure   --    0.748 
  Optimal 0 (0.0) 0 (0.0)   9 (7.5) 8 (6.2)  
  Pre-hypertension 0 (0.0) 0 (0.0)   47 (39.2) 44 (34.1)  
Grade 1 hypertension 133 (100.0) 150 (100.0)   47 (39.2) 59 (45.7)  
Grade 2-4 hypertension 0 (0.0) 0 (0.0)   17 (14.2) 18 (14.0)  
TC, mg/dL   0.155    0.760 
<160 7 (5.5) 4 (2.8)   7 (5.9) 5 (3.8)  
160-199 41 (32.0) 40 (28.0)   40 (33.6) 39 (30.0)  
200-239 56 (43.8) 61 (42.7)   51 (42.9) 58 (44.6)  
240-279 24 (18.8) 33 (23.1)   20 (16.8) 25 (19.2)  
≥280 0 (0.0) 5 (3.5)   1 (0.8) 3 (2.3)  
HDL-C, mg/dL 
  
0.905    0.589 
<35 2 (1.6) 1 (0.7)   3 (2.5) 2 (1.5)  
35-44 10 (7.8) 11 (7.7)   9 (7.6) 11 (8.5)  
45-49 10 (7.8) 9 (6.3)   2 (1.7) 7 (5.4)  
50-59 32 (25.0) 41 (28.7)   29 (24.4) 30 (23.1)  
≥60 74 (57.8) 81 (56.6)   76 (63.9) 80 (61.5)  
 
Values are presented as number (%). TC, total cholesterol; HDL-C, high-density lipoprotein-cholesterol.
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Table 3: Estimated absolute 10-year CV events (%) in the usual care group and DASH counselling group 
 
Ten-year risk (%) Mean (SD)  Within-group differences (95%CI)*  Between-group differences (95%CI)† 
 Baseline 6 
months 
12 
months 
 6 months P 12 months P  6 months P 12 months P 
Males              
  Usual care 2.12 
(1.43) 
1.90 
(1.39) 
1.90 
(1.22) 
 -0.22 (-0.35 
to -0.09) 
0.001 -0.22 (-0.35 
to -0.10) 
0.001  --  --  
  Intervention 2.31 
(1.42) 
1.98 
(1.27) 
1.94 
(1.20) 
 -0.34 (-0.50 
to -0.17) 
<0.001 -0.38 (-0.53 
to -0.22) 
<0.001  --  --  
  Intervention vs usual care --    --     -0.12 (-0.33 
to 0.08) 
0.244 -0.16 (-0.36 
to 0.04) 
0.111 
Females              
  Usual care 3.88 
(4.85) 
3.58 
(4.96) 
3.07 
(4.14) 
 -0.30 (-0.70 
to 0.10) 
0.135 -0.82 (-1.16 
to -0.48) 
<0.001  --  --  
  Intervention 4.28 
(5.07) 
3.81 
(5.83) 
3.39 
(4.04) 
 -0.47 (-1.01 
to 0.08) 
0.094 -0.89 (-1.25 
to -0.52) 
<0.001  --  --  
  Intervention vs usual care --    --     -0.13 (-0.82 
to 0.56) 
0.717 -0.03 (-0.49 
to 0.42) 
0.889 
Total              
  Usual care 2.98 
(3.64) 
2.72 
(3.70) 
2.47 
(3.07) 
 -0.26 (-0.47 
to -0.06) 
0.013 -0.51 (-0.69 
to -0.33) 
<0.001  --  --  
  Intervention 3.37 
(3.96) 
2.96 
(4.45) 
2.72 
(3.15) 
 -0.41 (-0.71 
to -0.10) 
0.009 -0.65 (-0.86 
to -0.44) 
<0.001  --  --  
  Intervention vs usual care --    --     -0.13 (-0.50 
to 0.23) 
0.477 -0.08 (-0.33 
to 0.18) 
0.568 
 
CHD, coronary heart disease; SD, standard deviation; CI, confidence interval. 
*Differences were calculated from 6-month follow-up between baseline, and 12-month follow-up between baseline, respectively. 
†Adjusted for gender, age, BMI, route into study (general outpatient clinics, or responding to the invitations from community health seminars), level of education, monthly 
household income, family history of hypertension, number of comorbidities, and baseline blood pressure measures. 
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Table 4: Factors associated with no improvements in 10-year CV risks 
 
 Model 1   Model 2*   Model 3†  
Variable cOR (95%CI) P  aOR (95%CI) P  aOR (95%CI) P 
Gender, male 1.24 (0.87 - 1.77) 0.227  1.60 (1.03 - 2.49) 0.035  1.68 (1.12 - 2.52) 0.012 
Age, <55 years 1.35 (0.94 - 1.93) 0.107  1.50 (0.99 - 2.28) 0.057  1.49 (1.00 - 2.23) 0.049 
Current smokers 1.77 (0.90 - 3.48) 0.099  2.86 (1.26 - 6.45) 0.012  2.93 (1.35 - 6.36) 0.007 
Education, ≤ junior 
secondary 
1.14 (0.80 - 1.63) 0.474  1.85 (1.19 - 2.90) 0.007  1.75 (1.15 - 2.66) 0.009 
Dining out 1.60 (0.92 - 2.78) 0.095  1.89 (1.05 - 3.41) 0.034  1.85 (1.03 - 3.32) 0.038 
Current drinker 1.32 (0.76 - 2.27) 0.324  1.09 (0.56 - 2.11) 0.800  --  
Family history of 
hypertension 
        
  No history 1.00 (Ref)   1.00 (Ref)   --  
  Presence 0.90 (0.61 - 1.33) 0.591  0.88 (0.58 - 1.33) 0.539    
Treatment         
  Usual care 1.00 (Ref)   1.00 (Ref)   --  
  DASH counselling 1.01 (0.71 - 1.43) 0.970  0.99 (0.68 - 1.44) 0.952    
Household income 
/month 
        
  <US$1,290 1.00 (Ref)   1.00 (Ref)   --  
  $1,290 - $2,579 1.18 (0.63 - 2.19) 0.607  0.95 (0.48 - 1.89) 0.882    
  $2,580 - $3,869 1.29 (0.68 - 2.46) 0.439  1.03 (0.50 - 2.10) 0.941    
  $3,870 - $5,159 1.71 (0.89 - 3.28) 0.106  1.45 (0.70 - 3.02) 0.318    
  ≥$5,160 1.46 (0.79 - 2.71) 0.229  1.18 (0.56 - 2.46) 0.666    
Comorbidities         
  No comorbidities 1.00 (Ref)   1.00 (Ref)   --  
  With comorbidities 1.30 (0.41 - 4.10) 0.653  1.40 (0.38 - 5.18) 0.617    
 
cOR, crude odds ratio; aOR, adjusted odds ratio; CI, confidence interval; Ref, reference; DASH, Dietary 
Approaches to Stop Hypertension. Current smokers referred to those who were currently smoking tobacco on a 
consistent basis as regular lifestyle behaviour. Dining out refers to going out for the main meal of the day more 
than 4 times in a typical week.  
 
*Model 2 adjusted for other independent variables listed.  
†Model 3 (final model) was constructed using a backward stepwise algorithm that allowed for covariate re-entry 
with all covariates having p values of ≤0.10 retained in the model. 
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